Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial
Inhaled iloprost is an effective therapy for patients with pulmonary arterial hypertension (PAH); however, some patients experience extended inhalation times when using the V10 formulation (10.0 µg/mL) to deliver a 5 -µg dose (at mouthpiece) and are at risk of incomplete inhalations and reduced inha...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-09-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045894018798921 |